Question to the Ministry of Defence:

To ask the Secretary of State for Defence, what criteria are applied by the Defence Medical Services to distinguish the adverse effects caused by the prescribing of Lariam (Mefloquine) to service personnel as an anti-malarial prophylaxis and those caused by post traumatic stress disorder; what treatment options are available for alleviating the effects of Lariam toxicity; and how many service personnel have been discharged in each of the past 10 years as a result of Lariam toxicity effects.

People taking mefloquine (also known as Larium) can experience abnormal dreams, symptoms of depression and anxiety, and more rarely psychiatric symptoms such as hallucinations, agitations and psychosis have also been reported. This differs to Post Traumatic Stress Disorder (PTSD) where very specific criteria must be met to establish a diagnosis. Essential to this diagnosis is that the individual will have been exposed to an extremely threatening or horrific event or a series of events.

Given the specifics required for the diagnosis of PTSD, is it unlikely for those presenting with any side effects of taking mefloquine to be confused with that of PTSD.

The Ministry of Defence does not recognise the term ‘Larium toxicity’ however, the side effects that may be experienced whilst taking mefloquine will be treated according to the diagnosis; for example, if the patient is experiencing depressive symptoms, the treatment for depression will be instigated.

The information requested about the numbers of personnel discharged over the previous 10 years whilst experiencing symptoms related to taking mefloquine, is not held centrally and could be provided only at disproportionate cost.